Dermorphin for Health & Longevity

Evidence Review created on 10/05/2026 using AI4L / Opus 5.5

Also known as: Dermorphine

Motivation

Dermorphin is a short chain of seven amino acids found in the skin of South American tree frogs of the genus Phyllomedusa. It attaches to the same nerve-cell docking sites in the brain, spinal cord and gut that morphine acts on, and most laboratory work on it has asked how tightly and how selectively it binds there. Its chemistry is unusual: one building block is a mirror image of the form life normally uses, which changes how the body’s protein-splitting enzymes handle it.

The compound reaches people in two very different ways. In the Amazon, the raw skin secretion containing it — called kambô or sapo — has long been used by indigenous communities in short, intense rituals, a practice that has since spread to cities in Europe and North America. In medicine, it was given to surgical patients in Italian hospitals in the mid-1980s and studied for pain relief, and decades later it surfaced as an injected substance in horse racing.

This review examines what the published record shows about dermorphin for health- and longevity-minded adults: how it works, what the small human and larger animal records contain, which harms are documented, and where evidence is absent.

Benefits - Risks - Protocol - Conclusion

Recommended Reading

This section collects high-level overviews of dermorphin and the frog secretion that contains it, chosen for breadth rather than for any single finding.

• Rediscovery of old drugs: the forgotten case of dermorphin for postoperative pain and palliation - Hesselink & Schatman, 2018

  The single best overview of the human record: it reconstructs the 1980s pharmacology, reports the 1985 surgical trial in detail, and asks why development stopped.

• The dermorphin peptide family - Melchiorri & Negri, 1996

  A review by the discovering laboratory — which collaborated with the peptide’s industrial patent holder — covering the family, receptor selectivity, behaviour in rodents and primates, and tolerance profile against morphine.

• The Amazonian kambô frog Phyllomedusa bicolor (Amphibia: Phyllomedusidae): Current knowledge on biology, phylogeography, toxinology, ethnopharmacology and medical aspects - Nogueira et al., 2022

  Integrates frog biology, ritual practice, secretion chemistry and medical complications, giving the context needed to separate dermorphin itself from the mixture it occurs in.

• Phyllomedusa bicolor skin secretion and the Kambô ritual - den Brave et al., 2014

  A concise clinical description of how the secretion is applied and which of its peptides drive which effects — useful for judging what ritual reports can and cannot say about dermorphin.

• Dermorphin tetrapeptide analogs as potent and long-lasting analgesics with pharmacological profiles distinct from morphine - Mizoguchi et al., 2011

  Explains why most modern work uses shortened, stabilised fragments rather than dermorphin itself, and what that structural change does to potency and side-effect profile.

No content from the priority experts is listed because none was found: two independent searches per platform (web search and the site’s own search) returned nothing on dermorphin or kambô, which is unsurprising for a compound with no legal human supply and no consumer market.

Grokipedia

• Dermorphin

  A long, reference-dense entry covering isolation, structure, biosynthesis, pharmacology, analogs, the 1985 surgical trial, and the racing-doping episode with its detection methods.

Examine

No Examine article on dermorphin exists. Examine covers supplements and nutrition compounds sold to consumers; dermorphin is an injectable research peptide with no marketed product and no supplement market, so it falls outside that scope.

ConsumerLab

No ConsumerLab article on dermorphin exists. ConsumerLab tests and reviews commercially sold supplements and foods; dermorphin is not sold as a supplement, so no product review or purity test exists.

Systematic Reviews

No systematic reviews or meta-analyses for Dermorphin were found on PubMed as of October 2, 2026.

Neither side of the trade-off is represented: no systematic review or meta-analysis covers dermorphin’s analgesic benefit, and none covers its harms. The nearest adjacent evidence synthesis, Kambo Administration and Its Association With Sudden Death: Clinical and Forensic Perspectives From a Systematic Review (Sacco et al., 2025), reviews deaths after ritual use of the whole Phyllomedusa bicolor secretion rather than the isolated peptide, and so is cited in the risk items instead of listed here.

Mechanism of Action

Dermorphin (H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH₂) is a selective agonist (activator) at the μ-opioid receptor (the nerve-cell docking site that mediates morphine’s pain relief). Activation opens potassium channels and closes calcium channels, damping nerve signalling in spinal pain pathways, brainstem circuits and the gut wall. Its defining feature is D-alanine in position 2 — a mirror-image amino acid that keeps it stable in stored plasma samples, unlike the ordinary L-form (Guan et al., 2013); its first four amino acids are the minimum active sequence (Broccardo et al., 1981).

Key pharmacological properties. Selectivity is high for μ over δ- and κ-opioid receptors (two other opioid docking-site types) (Negri et al., 2000). Distribution is dominated by rapid clearance: plasma half-life (time for the blood level to halve) was 1.3 minutes in rats, with breakdown in liver and kidney and fragments in bile (Negri & Improta, 1984); in horses the elimination half-life was 0.76 hours (Robinson et al., 2015). Human clearance is unmeasured. Metabolism runs through peptide-splitting enzymes (peptidases), not the cytochrome P450 (CYP) liver enzymes that process most drugs, with a four-amino-acid fragment the main product in human liver preparations (Castro et al., 2021). Penetration into the brain from the blood is poor, which is why spinal delivery was used (a 2018 narrative review).

Competing explanations. The discovering group attributed its effects wholly to μ-receptor activation (Melchiorri & Negri, 1996), while the human spinal-reflex study found naloxone reversed only about half the effect, pointing to more than one spinal opioid receptor population (Sandrini et al., 1986).

Historical Context & Evolution

Dermorphin was isolated in 1981 from Phyllomedusa sauvagei skin by Vittorio Erspamer’s group in Rome, which immediately recorded “exceptionally intense and long-lasting” opioid actions and named it from “derm” and “morphine” (a 2018 narrative review). The original interest was analgesia (pain relief): in rats, intracerebroventricular (into the brain’s fluid spaces) doses produced antinociception (reduced pain response) at 13–23 pmol, where morphine needed 752–2,170 times more, and the peptide was about 39 times more potent than morphine on the guinea-pig ileum (isolated gut) preparation (Broccardo et al., 1981). That early pharmacology was produced jointly with Farmitalia-Carlo Erba, which patented the peptide family — a commercial interest in the compound’s prospects that sits alongside those early findings.

Interest as a health-optimisation agent came from two directions. The first was the Amazonian record: dried secretion (“sapo”) rubbed into skin burns was described as improving hunting stamina, sight and resistance to hunger, with up to 7% of its weight consisting of active peptides (Erspamer et al., 1993). The second was the 1985 result in surgical patients.

Opinion did not turn against dermorphin so much as drift away. No clinical paper ever cited the 1985 trial, development stopped, and the authors who later made the case for revisiting it — a group whose stated programme is repositioning forgotten drugs — argue that the spinal route was then unfashionable rather than discredited (Hesselink & Schatman, 2018). The evidence for and against remains thin on both sides; nothing has replicated or refuted it.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the only randomised human evidence is a single trial from one research group, and every other human finding comes from uncontrolled physiological experiments in small volunteer samples or from self-report after ritual use.

Medium 🟩 🟩

Prolonged Pain Relief Acting at the Spinal Cord

In 150 consecutive patients after elective surgery, a single intrathecal (into the fluid around the spinal cord) dose relieved pain for longer than intrathecal morphine or intramuscular pentazocine, and shortened hospital stay against pentazocine (Basso et al., 1985). An uncontrolled volunteer study placed the μ-receptor action in the spinal cord, raising the leg-withdrawal reflex threshold (Sandrini et al., 1986). The randomised controlled trial (RCT — a study allocating patients by chance) comes from one Italian group and was never replicated (Hesselink & Schatman, 2018).

Magnitude: 8.96 hours more analgesia than intrathecal morphine (43.41 ± 1.64 versus 34.45 ± 2.35 hours) and 32.62 hours more than intramuscular pentazocine (10.79 ± 2.23 hours); 36 and 66 percentage points fewer patients needed additional analgesics (22% versus 58% and 88%). No 95% confidence intervals (the range within which the true value probably lies) were reported.

Low 🟩

Self-Reported Gains in Well-Being and Stamina After Ritual Use of the Whole Secretion

Users of the frog secretion report lasting gains in well-being, and Amazonian practice describes greater hunting stamina and sharpened senses (Majić et al., 2021; Erspamer et al., 1993). Evidence is indirect: an uncharacterised peptide mixture on burns, not purified dermorphin, with outcomes from uncontrolled self-report.

Magnitude: 87.31% of 386 surveyed users reported increased personal well-being or life satisfaction; self-report with no control group.

Speculative 🟨

Transient Release of Growth Hormone, Prolactin and Thyroid-Stimulating Hormone ⭕️ Not Central to Health & Longevity

Infusion in healthy volunteers raised growth hormone, prolactin and thyroid-stimulating hormone; naloxone suppressed or blunted these rises (Degli Uberti et al., 1985). These single-dose shifts bear on pituitary physiology, not on any measured health outcome.

Lower Tolerance and Dependence Liability Than Morphine ⚠️ Conflicted

Rat infusion found less tolerance and dependence than morphine (Broccardo et al., 1981); the same lab later found tolerance within 48 hours, dose-dependently (Broccardo et al., 1985). Net reading: dose likely explains the gap; animal-only.

Pain Relief Without Central Sedation Via Peripherally Acting Fragments

Shortened dermorphin analogues relieved neuropathic (nerve-damage) pain in rats by acting on peripheral receptors (Tiwari et al., 2016; Gadepalli et al., 2024). Evidence is animal-only and tests different compounds, not dermorphin itself.

Protection Against Fentanyl-Induced Pauses in Breathing

Pretreatment abolished the apnea (pause in breathing) that a rapid fentanyl injection otherwise caused in anaesthetised rats, which the authors propose as a countermeasure (Zhuang et al., 2026). Animal-only; no human data.

Benefit-Modifying Factors

• μ-receptor gene variants: Common OPRM1 variants (the gene encoding the μ-opioid receptor) alter response to μ agonists generally; no dermorphin-specific gene study exists, so any effect is inferred from the drug class rather than measured.

• Peptidase activity rather than liver enzymes: Because clearance runs through peptide-splitting enzymes, not the CYP system, the usual CYP-based genetic predictors of opioid response do not apply (Castro et al., 2021).

• Baseline biomarkers: No baseline measurement predicts response. Pituitary hormone status is the one documented exception: patients with prolactin-secreting tumours showed no prolactin response at all (Degli Uberti et al., 1985).

• Sex differences: No study has compared men and women directly. Separate infusion studies enrolled only women or only men (Petraglia et al., 1985; Degli Uberti et al., 1985), and the surgical trial did not report results by sex, so sex-specific benefit is unexamined.

• Pre-existing conditions: Pituitary and adrenal disease alter the hormone responses; established opioid tolerance would be expected to blunt analgesia, though in rats fentanyl pretreatment did not change dermorphin’s breathing response (Zhuang et al., 2026).

• Age: Nobody above or below the surgical-patient range has been studied separately. Older adults clear peptides and tolerate opioids differently, so effects at the older end of the target range are unknown rather than reassuring.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: the only controlled human safety data come from one randomised trial by a single group, and all other human reports describe the whole frog secretion rather than the purified peptide.

Medium 🟥 🟥

No risk reaches Medium: the single randomised trial found no significant excess of any adverse event over its comparator arms (Basso et al., 1985), leaving only uncontrolled human case reports of whole-secretion exposure.

Low 🟥

Nausea, Vomiting, Urinary Retention and Headache After Spinal Administration ⚠️ Conflicted

Brainstem and bladder opioid activation drives vomiting, urinary retention and headache after intrathecal dosing, yet the randomised trial found no significant excess over its comparators (Basso et al., 1985). Earlier uncontrolled studies reported about half affected (a 2018 review). Net reading: reversible, numerically commoner than comparators but not significantly so.

Magnitude: Nausea or vomiting in 22% versus 14% of the intramuscular pentazocine comparison group, and urinary retention in 26% versus 18%; headache was reported in all three arms without a rate. Differences were not statistically significant, and no confidence intervals were reported.

Severe Low Blood Sodium with Seizures and Brain Swelling

Ritual use of the whole secretion with heavy water drinking has caused hyponatremia (dangerously low blood sodium) by triggering water-retaining hormone release, with seizures and one fatal brain swelling (Leban et al., 2016; Tran et al., 2025). Evidence is indirect: a peptide mixture on burns, not purified dermorphin.

Magnitude: Sodium fell to 116 mmol/L in the reported case, with plasma osmolality (a measure of how concentrated the blood is) at 251 mOsm/kg against an inappropriately high urine value of 523 mOsm/kg; case reports with no control group.

Sudden Death Reported After Ritual Whole-Secretion Use

A forensic case and a systematic review document deaths after kambô ceremonies, attributed to cardiac events and oesophageal rupture (Aquila et al., 2018; Sacco et al., 2025). Again indirect: mixture, route and setting all differ from supervised dermorphin.

Magnitude: Direction only — a small number of deaths across a decade of reports; the literature gives no incidence figure because exposure denominators are unknown, and there is no control group.

Violent Vomiting and Its Complications, Including Oesophageal Rupture

The secretion provokes intense vomiting, which has torn the oesophagus (Boerhaave syndrome) and needed surgical repair (Darlington & Copertino, 2023). This is indirect: dermorphin contributes only part of the gut effect, as other peptides in the mixture drive most of it (den Brave et al., 2014).

Magnitude: Direction only — single case reports of rupture after repeated forceful vomiting; no rate and no control group are available.

Muscle Injury, Inflammatory Muscle Disease and Kidney Failure

Rhabdomyolysis (muscle breakdown releasing its contents into the blood) followed seizures in one poisoning case, dermatomyositis (an inflammatory muscle disease) followed repeated ritual use, and a poisoning series includes acute kidney failure (Campodónico et al., 2019; de la Vega et al., 2020; Sacco et al., 2022). Indirect: whole-secretion exposures.

Magnitude: Creatine kinase (an enzyme that leaks from damaged muscle into the blood) rose from 8,479 to 107,216 IU/L in the rhabdomyolysis case; single cases with no control group.

Liver Injury

Toxic hepatitis with jaundice followed repeated ritual use in one user, and transaminases (liver enzymes released by damaged liver cells) and cholestasis (blocked bile flow) markers rose in numerous cases of the published poisoning series (Pogorzelska & Łapiński, 2017; Sacco et al., 2022). Indirect: whole-secretion exposure, not purified dermorphin.

Magnitude: Toxic hepatitis in 1 of 11 reviewed poisoning cases (9%), with liver-damage markers raised in numerous others; case series with no control group.

Acute Psychiatric Reactions

A psychotic episode was reported after frequent ritual use, and a user survey found a small minority reporting lasting mental-health problems they attributed to it (Roy et al., 2018; Majić et al., 2021). Indirect: a case report plus self-report on the whole secretion.

Magnitude: 1.81% of 386 surveyed users reported long-lasting mental health problems they ascribed to the secretion; uncontrolled self-report, no control group.

Nerve Injury with Lasting Weakness

Four days after injecting the secretion, one user developed progressive weakness of all four limbs and the face, with nerve-conduction testing confirming polyneuropathy (widespread nerve damage) and deficits remaining at three months (Mantilla-Pardo et al., 2026); lasting neuropsychiatric impairment is separately reported (Jauregui et al., 2025). Indirect: whole-secretion exposure.

Magnitude: Direction only — single case reports with residual motor deficit persisting at three months; the literature gives no incidence figure and no control group.

Fast Heart Rate and Blood-Pressure Swings

Blood-vessel-widening and opioid peptides produce tachycardia (a fast heart rate) and blood-pressure swings after ritual exposure, and intravenous dermorphin itself raised heart rate in horses (Sacco et al., 2022; Robinson et al., 2015). Indirect: whole-secretion cases plus an animal study.

Magnitude: Cardiovascular signs in 36% (4 of 11) of reviewed poisoning cases; case series with no control group.

Speculative 🟨

Suppression of Breathing

Rapid intravenous injection caused apnea (a pause in breathing) in anaesthetised rats via μ₁ receptors, recovering within half a minute (Zhuang et al., 2026). No human respiratory data exist; the basis is animal and mechanistic.

Tolerance and Physical Dependence

Continuous brain infusion in rats produced tolerance within 48 hours and a naloxone-precipitated withdrawal syndrome resembling morphine’s (Broccardo et al., 1985). No human repeated-dosing data exist, so the grade rests on animal work alone.

Slowed Gut Transit and Constipation

Intracerebroventricular or subcutaneous injection delayed gastric emptying and intestinal transit in rats, reversibly with naloxone (Broccardo et al., 1982). No human bowel data exist; the basis is animal work.

Blunting of the Stress-Hormone Axis

Infusion lowered cortisol (Degli Uberti et al., 1985) and suppressed drug-stimulated corticotropin (ACTH, the pituitary hormone driving cortisol) release in healthy men (Degli Uberti et al., 1985). These are single-dose hormone measurements, not clinical outcomes.

Suppression of the Reproductive Hormone Axis

Infusion lowered luteinizing hormone (the pituitary signal driving sex-hormone production) in women, reversibly with naloxone (Petraglia et al., 1985). These are single-dose hormone measurements, not clinical outcomes.

Risk-Modifying Factors

• μ-receptor gene variants: OPRM1 variants shift sensitivity to μ agonists as a class; no dermorphin-specific data exist, so inherited differences in respiratory or vomiting-related susceptibility are presumed rather than demonstrated.

• Baseline biomarkers: Excess antidiuretic hormone (which makes the kidneys retain water) plus heavy water intake is the documented amplifier of the severe harms (Leban et al., 2016); low baseline sodium or impaired kidney function would add to it (theoretical).

• Sex differences: Published severe poisoning cases are predominantly in women, but reporting is uncontrolled and ritual participation is not sex-balanced, so no sex-specific risk can be inferred (Sacco et al., 2022).

• Pre-existing conditions: Cardiac hypertrophy (a thickened heart muscle) featured in the forensic death case (Aquila et al., 2018); seizures, respiratory disease, raised pressure inside the skull and adrenal insufficiency (too little adrenal hormone output) are class-level amplifiers (theoretical).

• Age: Older adults are more susceptible to opioid respiratory depression and to sodium disturbance, and no study has included them for this compound; risk at the older end of the target range is unquantified.

Key Interactions & Contraindications

• Opioid analgesics (morphine, fentanyl, oxycodone): Monitor closely (theoretical) — additive effects on breathing are a class expectation, untested in humans. In rats the interaction was asymmetrical: dermorphin pretreatment blocked fentanyl-induced apnea, while fentanyl pretreatment did not blunt dermorphin’s (Zhuang et al., 2026).

• Opioid blockers (naloxone, naltrexone, nalmefene — drugs that occupy the receptor without activating it): Caution — antagonism, used deliberately for reversal: naloxone reversed roughly half the spinal reflex effect in volunteers (Sandrini et al., 1986) and abolished analgesia while relieving persistent vomiting (a 2018 review).

• Sedatives and alcohol (diazepam, zolpidem, pregabalin, ethanol): Avoid (theoretical) — additive central and respiratory depression is a class effect; no dermorphin study exists. Mitigation is omission, not dose separation.

• Antiemetic drugs (domperidone — medications that suppress nausea and vomiting): Beneficial — in open studies preceding the randomised trial, pretreatment cut nausea and vomiting from about 50% to under 20%, given before dosing rather than as rescue (a 2018 review).

• Drugs that lower blood sodium (thiazide diuretics — antihypertensive medications that increase urine output; desmopressin; serotonin-reuptake-inhibitor antidepressants such as sertraline): Caution (theoretical) — additive risk of dangerously low blood sodium; monitor sodium and avoid fluid loading (Leban et al., 2016).

• Over-the-counter agents (loperamide, diphenhydramine, dextromethorphan): Caution (theoretical) — loperamide adds peripheral opioid slowing of gut transit; sedating antihistamines and dextromethorphan add drowsiness. Separate timing or omit.

• Anti-inflammatories and paracetamol (ibuprofen, naproxen, acetaminophen): No interaction expected (theoretical) — mechanisms differ and clearance is by peptidases rather than liver CYP enzymes, so no shared pathway exists (Castro et al., 2021).

• Supplements with opioid or sedative activity (kratom, valerian, melatonin, kava): Caution (theoretical) — kratom alkaloids activate the same receptor and the others add sedation; no combination has been tested in any species. Avoid combining.

• δ-opioid peptides in the same secretion (deltorphins): Caution (theoretical) — co-injection into rat brain produced synergistic pain relief at doses inactive alone, so the natural mixture is not simply additive (Negri et al., 1995); no human data exist. Avoid combined exposure.

• Other interventions — ritual co-use with ayahuasca: Caution — in one poisoning case ayahuasca preceded the secretion by 12 hours, confounding attribution of vomiting, seizures and sodium loss (Campodónico et al., 2019); avoid same-day co-use.

Populations who should avoid Dermorphin:

• Anyone without a lawful, supervised route of administration, since no product ever reached the market (Hesselink & Schatman, 2018) and US law requires approval before marketing — US Food and Drug Administration (FDA), Unapproved Drugs
• People with respiratory compromise, including severe chronic obstructive pulmonary disease and untreated obstructive sleep apnea — avoid (theoretical)
• People with raised pressure inside the skull or recent head injury — avoid (theoretical)
• People with opioid use disorder, or taking an opioid blocker — avoid (theoretical)
• People with structural heart disease, such as the left ventricular hypertrophy found in the one forensic death (Aquila et al., 2018)
• People prone to low blood sodium or taking sodium-lowering drugs (Leban et al., 2016); also those with adrenal insufficiency — avoid (theoretical)
• Pregnant or breastfeeding women and children — avoid (theoretical); no reproductive or paediatric data exist
• People with pituitary tumours, in whom the measured hormone responses were absent or unpredictable (Degli Uberti et al., 1985)

No source gives numeric thresholds for any of these populations: there is no product label, no guideline and no published trial exclusion list for dermorphin, so the categories are named without numbers.

Risk Mitigation Strategies

Parameters below follow common practice unless cited.

• Supervised research settings only: No marketed product, label or human dosing standard exists (Hesselink & Schatman, 2018; Unapproved Drugs), so self-administration carries unquantified risk of respiratory suppression; this mitigates exposure to an agent with no safety dossier.

• Opioid blocker immediately available: Naloxone reverses dermorphin’s effects in humans, though incompletely — about half the spinal effect in one study — mitigating breathing suppression and persistent vomiting (Sandrini et al., 1986).

• No forced water loading around exposure: Drinking several litres during ritual use contributed, alongside vomiting and inappropriate antidiuretic hormone release, to the reported hyponatremic seizures and brain swelling; limiting intake to thirst lowers that harm (Tran et al., 2025).

• Sodium testing on neurological symptoms: Headache, confusion, vomiting or seizure after exposure warrants immediate serum sodium and osmolality, since reported cases presented at 116–120 mmol/L (Leban et al., 2016; Campodónico et al., 2019).

• Antiemetic pretreatment: Pretreatment with domperidone cut the incidence of nausea and vomiting from about 50% to under 20% in the early intrathecal studies, mitigating vomiting and its complications (a 2018 review by Hesselink & Schatman).

• Avoidance of other central depressants: Combining μ agonists with alcohol, benzodiazepines (sedative anti-anxiety drugs) or further opioids compounds respiratory suppression; separating or omitting them mitigates the main lethal mechanism of this drug class.

• Cardiac screening before repeated ritual use: Undetected structural heart disease featured in the one forensic death; evaluation before repeated exposure mitigates sudden cardiac events (Aquila et al., 2018).

Therapeutic Protocol

No standard protocol exists and no practitioner or clinic uses dermorphin therapeutically: the compound never re-entered clinical use after the 1985 trial and has no marketed product or label (Hesselink & Schatman, 2018), and US law requires approval before any new drug is marketed (Unapproved Drugs). The regimens below are the historical research exposures reported in the literature, recorded for completeness; parameters without a citation (timing, cycling, titration) reflect common practice in the drug class, not any dermorphin protocol.

• Historical surgical regimen: A single intrathecal dose of 20 µg, given once after elective surgery by anaesthetists in Italian hospitals, was the only regimen ever tested in a randomised trial (Basso et al., 1985).

• Historical endocrine-probe regimen: Intravenous infusion of 5.5 µg/kg/min for 30 minutes was used in volunteer hormone studies, chosen as a research probe rather than a therapeutic dose (Degli Uberti et al., 1985).

• Competing approaches: The only published argument for current use favours spinal delivery for post-surgical and palliative pain; the competing line of work abandons the parent peptide for stabilised fragments and hybrids (Hesselink & Schatman, 2018; Hochrainer et al., 2024).

• Route: Oral administration is ineffective and injected peripheral dosing reaches the brain poorly, which is why spinal delivery was selected; intranasal and oral activity has been engineered only into analogues (Deigin et al., 2025).

• Half-life: No human value is published; plasma half-life was 1.3 minutes in rats and 0.76 hours in horses, far shorter than the analgesia observed after spinal dosing (Negri & Improta, 1984; Robinson et al., 2015).

• Single versus split dosing: Splitting was never studied; a single spinal dose controlled pain without further analgesics in about 80% of patients, so repeat dosing was not required (Basso et al., 1985).

• Time of day: No study compared timings. The surgical dose was given once after the operation and the volunteer exposure was a single 30-minute infusion, so no hour is favoured (Basso et al., 1985; Degli Uberti et al., 1985).

• Gene variants: No gene-based dosing guidance exists. OPRM1 variants modify μ agonist response generally, and CYP-based dose adjustment is irrelevant because clearance is peptidase-driven (Castro et al., 2021).

• Sex: No dose difference has been examined; the volunteer endocrine studies enrolled women and men separately at the same infusion rate (Petraglia et al., 1985; Degli Uberti et al., 1985), and the surgical trial did not report dosing by sex.

• Age: Nothing is published outside the adult surgical range. Reduced respiratory reserve and altered fluid handling in older adults argue for extra caution at the older end of the target range.

• Baseline biomarkers: No biomarker guides dosing; pituitary disease is the only documented modifier of the measured responses (Degli Uberti et al., 1985).

• Pre-existing conditions: Established opioid tolerance, respiratory disease and adrenal insufficiency would all be expected to change response, and none has been studied for this compound.

Discontinuation & Cycling

• Not a chronic therapy: Every documented human exposure was a single dose — one spinal injection or one short infusion — so no lifelong or long-term regimen exists to discontinue (Basso et al., 1985).

• Withdrawal effects: Continuous brain infusion in rats produced naloxone-precipitated withdrawal resembling morphine’s, with tolerance developing dose-dependently; earlier rat work found both less marked. No human withdrawal is described (Broccardo et al., 1985; Broccardo et al., 1981).

• Tapering: No taper protocol exists or is applicable, since repeated human dosing has never been studied; tapering is standard practice only after sustained opioid exposure.

• Cycling: Cycling has never been tested. Rat data show tolerance developing within 48 hours of continuous infusion, which is the only mechanistic reason anyone might propose spacing doses (Broccardo et al., 1985).

Sourcing and Quality

• No pharmaceutical-grade product exists: Dermorphin was never marketed as a medicine, so there is no licensed manufacturer, no official quality standard and no labelled strength to verify against (Hesselink & Schatman, 2018).

• No brand or compounding pharmacy can be named: None operates legitimately: federal law requires approval before any new drug is marketed for human use in the United States (Unapproved Drugs), and dermorphin never progressed past early clinical research (Hesselink & Schatman, 2018).

• What a purity document would have to show: Mass-spectrometric confirmation of the seven-amino-acid sequence and quantified content, since the material sold for research is synthetic and its identity cannot be inferred from appearance (Guan et al., 2013).

• Mirror-image variant and stability: The L-alanine diastereomer (the same molecule built with the ordinary, non-mirrored amino acid) is unstable in plasma and must be distinguished analytically from dermorphin, which itself stays stable at ambient temperature — defeating casual quality checks (Guan et al., 2013).

• Related peptides are easily confused with the parent: Peptide chemists have produced a large family of dermorphin variants, and anti-doping laboratories screen for seventeen of them, so a vial’s contents cannot be assumed from its description (Steel et al., 2014).

• Raw frog secretion is a different product entirely: Kambô sticks are an uncharacterised mixture of dozens of peptides whose dermorphin content is unmeasured and variable (Erspamer et al., 1993).

Practical Considerations

• Time to effect: After spinal injection, analgesia was established early and ran for roughly 43 hours from a single dose; after the whole secretion is applied to skin burns, gut and cardiovascular effects begin within minutes (Basso et al., 1985; Erspamer et al., 1993).

• Common pitfall — expecting oral or injected systemic activity: Peripheral dosing penetrates the brain poorly (a 2018 narrative review) and the peptide is destroyed rapidly (Negri & Improta, 1984), so the spinal route carried the clinical result.

• Common pitfall — treating kambô as dermorphin: The secretion contains many unrelated active peptides, and most of its dramatic effects are not opioid; evidence about one does not transfer to the other (den Brave et al., 2014).

• Common pitfall — blaming water loading alone: Drinking large volumes during rituals worsens the sodium emergencies, but a recent case report traced it mainly to venom-triggered release of the water-retaining hormone, so limiting water lowers rather than removes the risk (Kelly et al., 2025).

• Regulatory status: Dermorphin never progressed past early clinical research to a marketed medicine (Hesselink & Schatman, 2018), and marketing an unapproved new drug for human use is prohibited in the United States (Unapproved Drugs).

• Anti-doping status: The World Anti-Doping Agency (WADA), which sets sport’s banned-substance rules, lists no dermorphin entry; its S0 category prohibits unapproved substances at all times (Prohibited List).

• Cost and accessibility: There is no legitimate supply at any price; detection assays for human urine and equine samples exist precisely because the only circulating material is illicit (Castro et al., 2020; Guan et al., 2013).

Interaction with Foundational Habits

• Sleep: Indirect and undocumented for this compound. μ agonists as a class fragment sleep architecture and worsen sleep-disordered breathing, and the rat finding of μ₁-mediated apnea gives a mechanism, but no sleep study of dermorphin exists in any species (Zhuang et al., 2026).

• Nutrition: Direct and blunting on gut motility. Dermorphin delayed gastric emptying and intestinal transit in rats through both central and peripheral receptors, reversibly with naloxone — the familiar opioid constipation effect, arguing for fluid and fibre adequacy rather than any specific diet (Broccardo et al., 1982).

• Exercise: Indirect and potentially harmful. Analgesia masks injury signals, and the peptide was injected undetected into racehorses until detection assays were developed; no human study has examined training, recovery or performance (Guan et al., 2013).

• Stress management: Direct on the stress axis. Infusion lowered cortisol (Degli Uberti et al., 1985) and suppressed stimulated corticotropin release in healthy men (Degli Uberti et al., 1985), so acute exposure dampens the hormonal stress response; no study has asked whether this interacts usefully with breathing practice, meditation or sleep-based recovery.

Monitoring Protocol & Defining Success

Before any supervised exposure, the published harms point to a short baseline panel rather than a broad one: serum sodium and osmolality, because the severe reported events were electrolyte emergencies; creatine kinase, because muscle breakdown followed seizures in one case; alanine aminotransferase (a liver-cell enzyme), because liver markers rose in reported poisonings; and morning cortisol with prolactin if the endocrine effects are of interest, since those are the hormones human infusion studies actually moved. Afterwards, the useful cadence is driven by how fast those events appeared: sodium and osmolality within 2–6 hours of exposure and again at 24 hours whenever vomiting, headache, confusion or seizure occurs, creatine kinase and alanine aminotransferase at 24 hours if there was a seizure or prolonged vomiting, and hormone measurements repeated only if a baseline value was abnormal. Beyond 48 hours there is nothing to track, because no repeated-dose human exposure has been studied.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Serum sodium	135–145 mmol/L (standard reference range)	Safety check: the value that stops use — the documented life-threatening harm is acute low sodium	No sourced optimal functional range exists, so the conventional reference range is given; reported cases presented at 116–120 mmol/L (Leban et al., 2016; Campodónico et al., 2019)
Serum osmolality	275–295 mOsm/kg (standard reference range)	Safety check: separates water loading from inappropriate antidiuretic hormone release, which changes treatment	Pair with a simultaneous urine osmolality and urine sodium; reported cases showed 248–251 mOsm/kg serum against 448–523 mOsm/kg urine (Leban et al., 2016; Campodónico et al., 2019)
Creatine kinase	20–200 U/L (standard reference range; laboratory- and sex-dependent)	Safety check: detects muscle breakdown after seizures or prolonged vomiting	Creatine kinase (CK) is the muscle enzyme that leaks into blood when muscle is damaged; avoid measuring within 72 hours of hard exercise, which raises it independently; one case rose to 107,216 IU/L (Campodónico et al., 2019)
Alanine aminotransferase	7–55 U/L (standard reference range; laboratory- and sex-dependent)	Safety check: detects liver injury, which has followed ritual exposure	Alanine aminotransferase (ALT) is the enzyme released when liver cells are damaged; pair with bilirubin and gamma-glutamyl transferase (a bile-duct enzyme that rises when bile flow is blocked), since cholestasis markers also rose (Sacco et al., 2022)
Serum cortisol	5–25 µg/dL at 08:00 (standard reference range)	Expected to change: human infusion lowered cortisol and blunted the pituitary drive to produce it	Fasting not required but a fixed morning draw is, since the hormone follows a daily rhythm (Degli Uberti et al., 1985; Degli Uberti et al., 1985)
Serum prolactin	4–15 ng/mL (men), 4–23 ng/mL (non-pregnant women) (standard reference range)	Expected to change: human infusion raised prolactin, and absent response flags pituitary disease	Draw at rest; blood-draw stress, sleep and nipple stimulation all raise it, so repeat an isolated high value (Degli Uberti et al., 1985)

Qualitative markers worth tracking alongside the labs:

• Depth and duration of pain relief, and whether additional analgesia was needed
• Nausea, vomiting and its severity, and whether an antiemetic drug was required
• Breathing rate and depth, drowsiness and arousability in the hours after exposure
• Difficulty passing urine, and bowel movement frequency over the following days
• Mood, clarity of thinking and any craving or preoccupation with repeating exposure

Emerging Research

• No registered dermorphin trial: A ClinicalTrials.gov search for dermorphin returns no study of any status, so nothing is in human testing. A positive first-in-human trial would supply the first independent human evidence; continued absence leaves the 1985 result unverifiable.

• Completed ritual-use survey: NCT05042765, an observational survey of 102 participants at retreats using psychoactive plant and animal preparations, kambô among them, completed January 2022 with no results posted. Published results would characterise who uses the secretion; a null finding would leave harm reporting dependent on case reports.

• Proposal to revisit spinal delivery: The explicit call for new safety and efficacy studies of intrathecal dermorphin in post-surgical and palliative pain remains unanswered (Hesselink & Schatman, 2018). Nothing in the registry indicates such a study has begun.

• Hybrid and multi-target peptides: LENART01, a dermorphin-ranatensin hybrid acting at both opioid and dopamine receptors, produced pain relief in mice with fewer behavioural adverse effects than morphine (Hochrainer et al., 2024).

• Non-invasive analogue delivery: A linear dermorphin analogue relieved pain after intranasal dosing in rats, and ring-closed analogues after intragastric administration in mice, attacking the parent peptide’s central weakness — it has no useful oral activity (Deigin et al., 2025).

• Peripherally restricted fragments: A shortened dermorphin amide relieved chemotherapy-induced neuropathic pain in rats through peripheral receptors, the strategy most likely to separate analgesia from central opioid harms (Gadepalli et al., 2024).

• Evidence that could weaken the case: Rodent work shows the peptide itself causes apnea through μ₁ receptors, even while pretreatment blocked fentanyl-induced apnea (Zhuang et al., 2026). Human respiratory studies could confirm a hazard the 1985 trial was too small to detect.

• Growing toxicity surveillance: Case reporting on the whole secretion continues to accumulate, including a systematic review of deaths and a first brain-death report (Sacco et al., 2025; Tran et al., 2025). Further cases would sharpen the line between ritual use and any supervised peptide use.

• Human metabolism and detection: Work with human liver-enzyme preparations identified the tetrapeptide metabolite that anti-doping laboratories target, alongside validated human urine assays for the peptide and that metabolite (Castro et al., 2021; Castro et al., 2020). This makes undisclosed human use detectable and future exposure data more reliable.

Conclusion

Dermorphin is a short protein-like chain from frog skin that acts on the body’s main pain-signalling docking site — the one morphine acts on — with unusual precision and with a mirror-image building block that resists the enzymes which break down similar molecules. Its human record is strikingly thin: one randomised hospital study in surgical patients, where a single injection into the spinal fluid relieved pain for longer than the standard comparison, plus a few small volunteer experiments showing a raised pain threshold and brief hormone shifts. Nothing has replicated any of it.

The harms divide the same way. The controlled record shows the ordinary side effects of this drug class — nausea, vomiting, difficulty passing urine — no worse than the comparison drugs. The severe reported harms come from a different exposure: the raw frog secretion rubbed into skin burns during rituals, where heavy water drinking, violent vomiting and other active compounds have caused dangerous sodium loss, seizures, muscle, nerve and liver injury, and deaths. Breathing suppression and dependence are documented only in animals.

Much of the early work was done alongside a drug company that patented this family of molecules, and the modern case for revisiting it comes from authors whose stated programme is reviving forgotten drugs — interests that bear on how both sides of the record read. No product ever reached the market, nothing can be sourced lawfully, no human data describe how the body handles it, and the evidence remains too sparse to settle anything.

Top - Benefits - Risks - Protocol